PCM
LLY icon

Pointe Capital Management’s Eli Lilly LLY Stock Holding History

Pointe Capital Management’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Sell
1,184
-31
-3% -$31.4K 0.54% 43
2025
Q4 		$1.31M Hold
1,215
– – 0.65% 35
2025
Q3 		$927K Hold
1,215
– – 0.45% 50
2025
Q2 		$947K Buy
1,215
+19
+2% +$14.8K 0.49% 48
2025
Q1 		$988K Hold
1,196
– – 0.58% 44
2024
Q4 		$923K Sell
1,196
-21
-2% -$17.4K 0.53% 48
2024
Q3 		$1.08M Sell
1,217
-16
-1% -$14.4K 0.63% 35
2024
Q2 		$1.12M Sell
1,233
-70
-5% -$56K 0.69% 32
2024
Q1 		$1.01M Sell
1,303
-55
-4% -$39.1K 0.62% 37
2023
Q4 		$792K Sell
1,358
-65
-5% -$37.9K 0.55% 46
2023
Q3 		$764K Sell
1,423
-30
-2% -$15.5K 0.56% 45
2023
Q2 		$681K Hold
1,453
– – 0.51% 51
2023
Q1 		$499K Sell
1,453
-426
-23% -$144K 0.36% 67
2022
Q4 		$687K Sell
1,879
-125
-6% -$44.3K 0.53% 47
2022
Q3 		$648K Hold
2,004
– – 0.52% 50
2022
Q2 		$650K Sell
2,004
-100
-5% -$30K 0.48% 52
2022
Q1 		$602K Hold
2,104
– – 0.38% 67
2021
Q4 		$581K Sell
2,104
-104
-5% -$26.4K 0.35% 72
2021
Q3 		$510K Hold
2,208
– – 0.35% 79
2021
Q2 		$507K Hold
2,208
– – 0.36% 81
2021
Q1 		$412K Buy
2,208
+51
+2% +$9.98K 0.29% 89
2020
Q4 		$364K Sell
2,157
-482
-18% -$72K 0.31% 91
2020
Q3 		$391K Hold
2,639
– – 0.34% 83
2020
Q2 		$433K Sell
2,639
-79
-3% -$12.1K 0.39% 75
2020
Q1 		$377K Hold
2,718
– – 0.37% 69
2019
Q4 		$357K Hold
2,718
– – 0.3% 96
2019
Q3 		$304K Sell
2,718
-1,666
-38% -$185K 0.26% 107
2019
Q2 		$486K Buy
4,384
+11
+0.3% +$1.29K 0.4% 69
2019
Q1 		$567K Buy
4,373
+61
+1% +$7.42K 0.48% 61
2018
Q4 		$499K Sell
4,312
-1,245
-22% -$139K 0.49% 59
2018
Q3 		$596K Buy
5,557
+336
+6% +$33.6K 0.47% 61
2018
Q2 		$446K Sell
5,221
-555
-10% -$45.6K 0.38% 74
2018
Q1 		$447K Buy
5,776
+55
+1% +$4.43K 0.39% 77
2017
Q4 		$483K Sell
5,721
-195
-3% -$16.6K 0.39% 78
2017
Q3 		$506K Buy
5,916
+54
+0.9% +$4.43K 0.37% 82
2017
Q2 		$482K Sell
5,862
-151
-3% -$12.3K 0.35% 86
2017
Q1 		$506K Buy
+6,013
New +$482K 0.39% 79
2016
Q4 		– Sell
-6,225
Closed -$500K – 203
2016
Q3 		$500K Sell
6,225
-141
-2% -$11.3K 0.36% 86
2016
Q2 		$501K Buy
6,366
+2,500
+65% +$188K 0.36% 82
2016
Q1 		$278K Buy
3,866
+578
+18% +$43.7K 0.22% 120
2015
Q4 		$277K Buy
+3,288
New +$273K 0.2% 125

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Pointe Capital Management's LLY Position: Q1 2026 in Review

Pointe Capital Management reduced its Eli Lilly (LLY) stake by 2.6% in Q1 2026, selling an estimated $31.4K and leaving 1,184 shares worth $1.09M. The position accounts for 0.54% of the portfolio, ranked #43.

Pointe Capital Management first reported a position in LLY in Q4 2015 and has held it in 41 quarters since. The position peaked at $1.31M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Pointe Capital Management held 1,184 shares of Eli Lilly worth $1.09M as of Q1 2026.
  • Pointe Capital Management sold 31 Eli Lilly shares in Q1 2026, an estimated $31.4K.
  • Eli Lilly made up 0.54% of Pointe Capital Management's portfolio in Q1 2026, its #43 holding.
  • Pointe Capital Management first reported a position in Eli Lilly in Q4 2015 and has held it in 41 quarters since.
  • Pointe Capital Management's Eli Lilly position peaked at $1.31M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Pointe Capital Management's 13F filing for Q1 2026, filed 15 May 2026.